Skip to main content
. 2019 Jun 11;4:2. doi: 10.1186/s41199-019-0041-4

Table 3.

Pharmacologic and lifestyle interventions

Study Settings/Patients Study Design/Intervention Timing of intervention Assessment timepoints Measures Results Methodological Quality
Lydiatt et al. (2013) [24] 148 HNC pts.; Nebraska RCT. Intervention group received escitalopram pharmacotherapy for 16 weeks vs. placebo pill through their oncology team. before treatment started baseline, 2, 4, 6, 8, 10, 12, 16, 20, 24, and 28 weeks QIDS, MINI, QIDS-C, WQ-QOL, FIBSER (Frequency, Intensity, and Burden of Side Effects Rating) Prophylactic escitalopram reduced depression rates and improved QOL. Radiation group had highest rates of depression. 6
Capozzi et al. (2016) [25]

60 HNC pts.;

Canada

RCT. Intervention group received a lifestyle intervention (physician referral, health education for 6 sessions, behavior change support, individualized exercise program with resistance training, and group exercise setting 2x weekly). Control group was a delayed group of the same intervention. new diagnosis - randomized between immediate lifestyle intervention vs. 12 week delayed baseline, 12, 24, 36, 48 weeks physical activity, BMI, lean body mass and percentage body fat; QOL: FACT-HN; Depression: CES-D, Nutrition - patient generated subjective global assessment Delayed group were more able to complete intervention. No difference in body composition between groups. Potential benefit regardless of timing. No diff in QOL or depression - both declined at 12 weeks then improved at 24 weeks. 5